CANCER TREATMENT PHARMACEUTICAL COMPOSITION USING ANTI-MCT5 ANTIBODY

The purpose of the present invention is to provide a novel pharmaceutical composition that is cancer-specific and has few side-effects. Provided by the present invention is a pharmaceutical composition containing a monoclonal antibody that recognizes a polypeptide in an extracellular region of nativ...

Full description

Saved in:
Bibliographic Details
Main Authors SATOFUKA HIROYUKI, OKABE YOUKO, KATO DAI
Format Patent
LanguageChinese
English
Published 21.12.2018
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The purpose of the present invention is to provide a novel pharmaceutical composition that is cancer-specific and has few side-effects. Provided by the present invention is a pharmaceutical composition containing a monoclonal antibody that recognizes a polypeptide in an extracellular region of native MCT5. 本发明的目的在于提供有癌特异性且副作用少的新型药物组合物。本发明提供包含单克隆抗体的药物组合物，所述单克隆抗体识别天然的MCT5的胞外区的多肽。
Bibliography:Application Number: CN201780028138